Oruka Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Rhea-AI Summary
Oruka Therapeutics (Nasdaq: ORKA) reported Q4 and full-year 2025 results and a pipeline update. The company had $479.6 million in cash and marketable securities as of December 31, 2025. EVERLAST-A enrollment completed; Week 16 data now expected in 2Q 2026. ORCA-SURGE Phase 2 for ORKA-002 initiated, with data expected in 2027. Full-year 2025 R&D expense was $100.6 million and net loss was $105.4 million. ORKA-002 Phase 1 interim data showed ~75–80 day half-life, supporting twice-yearly maintenance dosing.
Positive
- Cash position of $479.6 million as of December 31, 2025
- EVERLAST-A enrollment completed, enabling Week 16 data in 2Q 2026
- Initiation of ORCA-SURGE Phase 2 for ORKA-002 with 2027 data target
- ORKA-002 Phase 1 interim half-life ~75–80 days, supporting twice-yearly dosing
Negative
- Full-year net loss $105.4 million in 2025
- Full-year R&D expense $100.6 million, up from $75.1 million (2024)
- Net cash used in operations $88.2 million for full-year 2025
News Market Reaction – ORKA
On the day this news was published, ORKA gained 25.04%, reflecting a significant positive market reaction. Argus tracked a peak move of +24.9% during that session. Argus tracked a trough of -4.9% from its starting point during tracking. Our momentum scanner triggered 47 alerts that day, indicating elevated trading interest and price volatility. This price movement added approximately $399M to the company's valuation, bringing the market cap to $1.99B at that time. Trading volume was very high at 3.5x the daily average, suggesting strong buying interest.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
ORKA was up 2.14% pre-release while close peers were mixed: ANAB up 4.83%, SVRA and RZLT down modestly, others little changed. This points to stock-specific factors rather than a broad biotechnology move.
Previous Earnings Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Nov 12 | Q3 2025 earnings | Positive | -6.8% | Highlighted strong cash and favorable ORKA-001 and ORKA-002 clinical progress. |
| Aug 11 | Q2 2025 earnings | Positive | +6.9% | Reported solid cash, growing R&D and wider net loss with pipeline advancing. |
| May 14 | Q1 2025 earnings | Positive | -2.6% | Strong cash runway through 2027 and progress on ORKA-001 and ORKA-002. |
| Mar 06 | FY 2024 earnings | Positive | +3.9% | Large 2024 fundraising, robust cash, and advancement of ORKA-001 and ORKA-002. |
| Nov 13 | Q3 2024 earnings | Positive | -6.4% | Reported over $475M raised, strong cash and accelerated clinical timelines. |
Earnings updates often highlighted strong cash and pipeline progress, but price reactions skewed slightly negative, with several selloffs on otherwise constructive updates.
Over the past five earnings cycles, Oruka consistently emphasized a strong cash position and rapid advancement of ORKA‑001 and ORKA‑002. Cash balances ranged from $351.5M to $500.9M, supporting plans through at least 2027, while R&D spend and net loss steadily increased as programs moved into and through Phase 1 and Phase 2a. Price reactions were mixed, including a -6.78% move on Q3 2025 results and a 3.87% gain on FY 2024, suggesting investor sensitivity to burn and valuation around these updates.
Historical Comparison
Past earnings updates for ORKA saw an average -1% move, with mixed reactions to similar cash-rich, pipeline-progress messages.
Across earnings cycles, Oruka moved from initial Phase 1 work into multiple Phase 2 trials for ORKA‑001 and ORKA‑002 while maintaining a substantial cash runway.
Regulatory & Risk Context
An amended S-3/A resale registration covers up to 39,425,806 shares for selling stockholders from prior financings. The company is not selling shares itself and will not receive proceeds from these resales, other than nominal warrant exercise prices. Registered shares represent a significant portion of the share count and create potential overhang if actively sold.
Market Pulse Summary
The stock surged +25.0% in the session following this news. A strong positive reaction aligns with Oruka’s pattern of investors rewarding clear pipeline milestones and robust liquidity. Prior earnings showed mixed stock moves despite solid cash, so a sizeable gain on this update could reflect comfort with $479.6M in cash plus visible 2026–2027 readouts. Investors would still need to monitor ongoing cash use, insider selling activity, and potential selling from registered resale holders under the existing S-3/A.
Key Terms
phase 2 medical
phase 1 medical
pasi 100 medical
il-23p19 medical
il-17a/f medical
monoclonal antibody medical
pharmacokinetic modeling medical
AI-generated analysis. Not financial advice.
ORKA-001 EVERLAST-A 16-week data now expected in 2Q 2026 following rapid enrollment, with longer-term follow-up data expected in 2H 2026
ORCA-SURGE Phase 2 trial of ORKA-002 in psoriasis initiated with data expected 2027
MENLO PARK, Calif., March 12, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis (PsO), today reported fourth quarter and full year 2025 financial results and provided a corporate update.
“We are very pleased with the progress of both our co-lead programs as we advance into what could be a transformative year for our company,” said Lawrence Klein, PhD, Chief Executive Officer of Oruka. “Given strong site engagement and enthusiasm, EVERLAST-A completed enrollment in December 2025, enabling us to bring our initial data release into the second quarter of 2026. Meanwhile, we are excited to be starting our Phase 2 efforts with ORKA-002, which we believe could be a very impactful program in psoriatic disease and HS.”
Fourth Quarter 2025 and Recent Business and Pipeline Updates
ORKA-001: A novel half-life extended IL-23p19 monoclonal antibody
- Enrollment in EVERLAST-A was completed in December 2025. As a result, the Company now expects to report Week 16 data for all patients in the second quarter of 2026. In addition, the Company plans to provide longer-term data, including Week 28 for all patients and 52-week follow-up for a portion of the cohort in the second half of 2026.
- The first patients were dosed in EVERLAST-B in December 2025 and enrollment is ongoing. EVERLAST-B is evaluating multiple induction regimens of ORKA-001, with a primary endpoint of PASI 100 at Week 16. Data from EVERLAST-B is anticipated in 2027 and will be used to support initiation of a Phase 3 program.
ORKA-002: A novel half-life extended IL-17A/F monoclonal antibody
- In February 2026, the Company initiated ORCA-SURGE, a Phase 2 trial designed to evaluate the safety and efficacy of ORKA-002 in moderate-to-severe PsO patients. The primary endpoint will be PASI 100 at Week 16. Maintenance dosing will evaluate the potential for twice-yearly dosing with ORKA-002. Data from ORCA-SURGE is anticipated in 2027.
- In January 2026, Oruka announced positive interim Phase 1 data demonstrating a half-life of approximately 75–80 days and pharmacokinetic modeling supporting twice-yearly maintenance dosing in psoriasis and quarterly dosing in HS.
- The Company is on track to initiate a Phase 2 trial of ORKA-002 for the treatment of moderate-to-severe hidradenitis suppurativa (HS) in the second half of 2026.
Additional updates
- In December 2025, the Company announced the addition of Chris Martin to its Board of Directors, adding significant commercial and business development expertise.
Fourth Quarter and Full Year 2025 Financial Results
Cash Position: As of December 31, 2025, Oruka had cash, cash equivalents and marketable securities of
Research and Development (R&D) Expenses: R&D expenses were
General and Administrative (G&A) Expenses: G&A expenses were
Other income, net: Other income, net was
Net Loss: Net loss was
About Oruka Therapeutics
Oruka Therapeutics is developing novel biologics designed to set a new standard for the treatment of chronic skin diseases. Oruka’s mission is to offer patients suffering from chronic skin diseases like plaque psoriasis the greatest possible freedom from their condition by achieving high rates of complete disease clearance with dosing as infrequently as once or twice a year. Oruka is advancing a proprietary portfolio of potentially best-in-class antibodies that were engineered by Paragon Therapeutics and target the core mechanisms underlying plaque psoriasis and other dermatologic and inflammatory diseases. For more information, visit www.orukatx.com and follow Oruka on LinkedIn.
Forward Looking Statements
Certain statements in this press release, other than purely historical information, may constitute “forward-looking statements” within the meaning of the federal securities laws, including for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, express or implied statements relating to Oruka’s expectations, hopes, beliefs, intentions or strategies regarding the future of its pipeline and business including, without limitation, Oruka’s ability to achieve the expected benefits or opportunities with respect to ORKA-001 and ORKA-002, including timelines to clinical and data release milestones, the details of its planned clinical studies, the potential dosing intervals of ORKA-001 and ORKA-002, the anticipated half-life of ORKA-002, as well as the Company’s cash runway. These forward-looking statements are based on current expectations and beliefs concerning future developments and their potential effects. There can be no assurance that future developments affecting Oruka will be those that have been anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond Oruka’s control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, those uncertainties and factors described under the heading “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in Oruka’s most recent filings with the Securities and Exchange Commission (SEC), including its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Should one or more of these risks or uncertainties materialize, or should any of Oruka’s assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Nothing in this press release should be regarded as a representation by any person that the forward-looking statements set forth therein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein and in Oruka’s SEC filings. Oruka does not undertake or accept any duty to make any updates or revisions to any forward-looking statements.
Investor Contact:
Alan Lada
(650)-606-7911
alan.lada@orukatx.com
| ORUKA THERAPEUTICS, INC. | ||||||||
| CONDENSED CONSOLIDATED BALANCE SHEETS | ||||||||
| (unaudited) | ||||||||
| (in thousands) | ||||||||
| December 31, | December 31, | |||||||
| 2025 | 2024 | |||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 46,935 | $ | 61,575 | ||||
| Marketable securities, current | 290,109 | 314,073 | ||||||
| Prepaid expenses and other current assets | 6,813 | 1,221 | ||||||
| Total current assets | 343,857 | 376,869 | ||||||
| Marketable securities, long-term | 142,539 | 18,069 | ||||||
| Property and equipment, net | 288 | 162 | ||||||
| Operating lease right-of-use assets | 1,830 | 876 | ||||||
| Other non-current assets | 103 | 43 | ||||||
| Total assets | $ | 488,617 | $ | 396,019 | ||||
| Liabilities and Stockholders’ Equity | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 4,155 | $ | 3,462 | ||||
| Accrued expenses and other current liabilities | 10,591 | 3,346 | ||||||
| Operating lease liability, current | 619 | 213 | ||||||
| Related party accounts payable and other current liabilities | 9 | 6,022 | ||||||
| Total current liabilities | 15,374 | 13,043 | ||||||
| Operating lease liability, non-current | 1,313 | 755 | ||||||
| Total liabilities | 16,687 | 13,798 | ||||||
| Commitments and contingencies | ||||||||
| Stockholders’ equity: | ||||||||
| Series B non-voting convertible preferred stock | 2,931 | 2,931 | ||||||
| Common stock | 49 | 37 | ||||||
| Additional paid-in capital | 657,561 | 463,018 | ||||||
| Accumulated other comprehensive income (loss) | 546 | (41 | ) | |||||
| Accumulated deficit | (189,157 | ) | (83,724 | ) | ||||
| Total stockholders’ equity | 471,930 | 382,221 | ||||||
| Total liabilities and stockholders’ equity | $ | 488,617 | $ | 396,019 | ||||
| ORUKA THERAPEUTICS, INC. | ||||||||||||||||
| CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS | ||||||||||||||||
| (unaudited) | ||||||||||||||||
| (in thousands, except share and per share data) | ||||||||||||||||
| Three Months Ended December 31, 2025 | Three Months Ended December 31, 2024 | Year Ended December 31, 2025 | Period from February 6, 2024 (inception) to December 31, 2024 | |||||||||||||
| Operating expenses: | ||||||||||||||||
| Research and development(1) | $ | 27,640 | $ | 25,503 | $ | 100,640 | $ | 75,060 | ||||||||
| General and administrative(1) | 6,791 | 4,815 | 21,411 | 13,063 | ||||||||||||
| Total operating expenses | 34,431 | 30,318 | 122,051 | 88,123 | ||||||||||||
| Loss from operations | (34,431 | ) | (30,318 | ) | (122,051 | ) | (88,123 | ) | ||||||||
| Other income (expense): | ||||||||||||||||
| Interest income | 4,849 | 4,533 | 16,630 | 5,863 | ||||||||||||
| Interest expense | — | — | — | (1,468 | ) | |||||||||||
| Other income (expense), net | (1 | ) | 4 | (12 | ) | 4 | ||||||||||
| Total other income, net | 4,848 | 4,537 | 16,618 | 4,399 | ||||||||||||
| Net Loss | (29,583 | ) | (25,781 | ) | (105,433 | ) | (83,724 | ) | ||||||||
| Net loss per share attributable to common stockholders, basic and diluted | $ | (0.45 | ) | $ | (0.49 | ) | $ | (1.85 | ) | $ | (3.87 | ) | ||||
| Net loss per share attributable to Series A non-voting convertible preferred stockholders, basic and diluted | $ | — | $ | (488.06 | ) | $ | — | $ | (3,873.25 | ) | ||||||
| Net loss per share attributable to Series B non-voting convertible preferred stockholders, basic and diluted | $ | (37.44 | ) | $ | (40.64 | ) | $ | (154.03 | ) | $ | (322.81 | ) | ||||
| Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted | 54,420,045 | 40,134,008 | 45,614,142 | 16,789,362 | ||||||||||||
| Weighted-average shares used in computing net loss per share attributable to Series A non-voting convertible preferred stockholders, basic and diluted | — | 1,299 | — | 495 | ||||||||||||
| Weighted-average shares used in computing net loss per share attributable to Series B non-voting convertible preferred stockholders, basic and diluted | 137,138 | 137,138 | 137,138 | 51,946 | ||||||||||||
| (1) Amounts include non-cash stock based compensation expense (including Paruka warrant obligation) as follows (in thousands): | ||||||||||||||||
| Three Months Ended December 31, 2025 | Three Months Ended December 31, 2024 | Year Ended December 31, 2025 | Period from February 6, 2024 (inception) to December 31, 2024 | |||||||||||||
| Research and development | $ | 2,307 | $ | 3,682 | $ | 17,019 | $ | 11,992 | ||||||||
| General and administrative | 1,808 | 1,468 | 7,221 | 2,927 | ||||||||||||
| Total | $ | 4,115 | $ | 5,150 | $ | 24,240 | $ | 14,919 | ||||||||
FAQ
When will Oruka (ORKA) report EVERLAST-A Week 16 data?
What cash runway does Oruka (ORKA) have after its December 31, 2025 cash balance?
What are the key design features and timeline for ORKA-002's Phase 2 ORCA-SURGE (ORKA)?
How did ORKA-002 Phase 1 interim data affect dosing expectations for ORKA (ORKA)?
What were Oruka's (ORKA) full-year 2025 R&D and net loss figures?
What near-term clinical catalysts should ORKA investors watch in 2026?
